A study of AJ-303 for the treatment of idiopathic pulmonary fibrosis
Latest Information Update: 24 Feb 2021
At a glance
- Drugs AJ 303 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 18 Feb 2031 As discussed with RDI, I have created this trial from annji pharmaceutical pipeline [http://www.ajpharm.com/wp/enaj303/]
- 24 Feb 2021 New trial record